RANKL/RANK control Brca1 mutation-driven mammary tumors

Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations in the breast cancer 1 (BRCA1) or BRCA2 genes markedly increase the risk for the development of breast cancer. Here, using two different mouse models, we show that genetic inactivation of the key osteoclast differentiation factor RANK in the mammary epithelium markedly delayed onset, reduced incidence, and attenuated progression of Brca1;p53 mutation-driven mammary cancer. Long-term pharmacological inhibition of the RANK ligand RANKL in mice abolished the occurrence of Brca1 mutation-driven pre-neoplastic lesions. Mechanistically, genetic inactivation of Rank or RANKL/RANK blockade impaired proliferation and expansion of both murine Brca1;p53 mutant mammary stem cells and mammary progenitors from human BRCA1 mutation carriers. In addition, genome variations within the RANK locus were significantly associated with risk of developing breast cancer in women with BRCA1 mutations. Thus, RANKL/RANK control progenitor cell expansion and tumorigenesis in inherited breast cancer. These results present a viable strategy for the possible prevention of breast cancer in BRCA1 mutant patients.

• Publication year

  2016

• Venue

  Cell Research

• Publication date

  2016-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cr.2016.69PMID 27241552PMCID 5129883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation

  2016cited by this paper
• STAT3 regulated ARF expression suppresses prostate cancer metastasis

  2015cited by this paper
• RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1

  2015cited by this paper
• XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway

  2014cited by this paper
• The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.

  2013cited by this paper
• Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

  2013cited by this paper
• Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

  2013cited by this paper
• Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells

  2013cited by this paper
• Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells.

  2013cited by this paper
• The shaping and functional consequences of the microRNA landscape in breast cancer

  2013cited by this paper
• Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture

  2012cited by this paper
• TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer

  2012cited by this paper
• Proliferative and Nonproliferative Lesions of the Rat and Mouse Mammary, Zymbal’s, Preputial, and Clitoral Glands

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Browser’s Notes

  2012cited by this paper
• Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.

  2011cited by this paper
• Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping

  2011cited by this paper
• RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

  2010cited by this paper
• Control of mammary stem cell function by steroid hormone signalling

  2010cited by this paper
• Progesterone induces adult mammary stem cell expansion

  2010cited by this paper
• Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

  2010cited by this paper
• Central control of fever and female body temperature by RANKL/RANK

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies

  2009cited by this paper
• A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability

  2008cited by this paper
• BRCA1 regulates human mammary stem/progenitor cell fate

  2008cited by this paper
• Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

  2007cited by this paper
• Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

  2007cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

  2006cited by this paper
• Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist

  2006cited by this paper
• Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity.

  2005cited by this paper
• Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ.

  2005cited by this paper
• Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer

  2005cited by this paper
• Somatic Mutation of p53 Leads to Estrogen Receptor α-Positive and -Negative Mouse Mammary Tumors with High Frequency of Metastasis

  2004cited by this paper
• Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues

  2003cited by this paper
• Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus

  2001cited by this paper
• The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡

  2000cited by this paper
• The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

  2000cited by this paper
• BRCA1 inhibition of estrogen receptor signaling in transfected cells.

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• RANK is essential for osteoclast and lymph node development.

  1999cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments

  year unknowncited by this paper

• Cancer Prevention Clinical Trials: Advances and Challenges

  2026cites this paper
• Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.

  2026cites this paper
• The receptor activator of nuclear factor κB ligand (RANKL) regulates the biological behavior of trophoblasts through the PI3K/Akt signaling pathway.

  2026cites this paper
• Insights from three decades of BRCA1/2 modeling in mice.

  2026cites this paper
• RANKL and CSF-1 are elevated in periovulatory follicular fluid of BRCA1 mutation carriers and increase proinflammatory signaling in fallopian tube epithelial cells

  2025cites this paper
• Risk-reducing mastectomy in healthy women with BRCA mutation: a narrative review

  2025cites this paper
• Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

  2025cites this paper
• PR+ progenitors contribute to all mammary epithelial lineages

  2025cites this paper
• Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  2025cites this paper
• RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells

  2025cites this paper
• Decoding breast cancer: insights into molecular pathways & therapeutic approaches

  2025cites this paper
• Anti-progestin therapy targets hallmarks of breast cancer risk

  2025cites this paper
• Surgical management of breast cancer: a review

  2025cites this paper
• Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

  2025cites this paper
• RANK/RANKL Signaling Pathway in Breast Development and Cancer.

  2025cites this paper
• Cells-of-Origin of Breast Cancer and Intertumoral Heterogeneity.

  2025cites this paper
• Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies

  2025cites this paper
• Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers

  2024cites this paper
• RANKL regulates differentially breast cancer stem cell properties through its RANK and LGR4 receptors.

  2024cites this paper
• Chemoprevention strategies in hereditary breast and ovarian cancer syndromes.

  2024cites this paper
• BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality

  2024cites this paper
• RANK in cancer-associated fibroblasts: A valuable prognostic determinant for metastasis in early-stage breast cancer patients

  2024cites this paper
• ELF5: A Molecular Clock for Breast Aging and Cancer Susceptibility

  2024cites this paper
• Novel Cancer Prevention Strategies in Individuals With Hereditary Cancer Syndromes: Focus on BRCA1, BRCA2, and Lynch Syndrome.

  2024cites this paper
• Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion

  2024cites this paper
• Correlation of RANK and RANKL with mammographic density in primary breast cancer patients

  2024cites this paper
• Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment.

  2023cites this paper
• RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer

  2023cites this paper
• Correlates of circulating osteoprotegerin in women with a pathogenic or likely pathogenic variant in the BRCA1 gene.

  2023cites this paper
• Choices for cancer prevention for women with a BRCA1 mutation? a personal view

  2023cites this paper
• RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer

  2023cites this paper
• Portable NMR for the investigation of models of mammographic density ex vivo: Androgens antagonise the promotional effect of oestrogen

  2023cites this paper
• Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer

  2023cites this paper
• A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer

  2023cites this paper
• The RANK–RANKL–OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer

  2023cites this paper
• Primary Prevention and Early Detection of Hereditary Breast Cancer

  2023cites this paper
• Α Humanized RANKL Transgenic Mouse Model of Progestin-Induced Mammary Carcinogenesis for Evaluation of Novel Therapeutics

  2023cites this paper
• Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer

  2023cites this paper
• Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

  2023cites this paper
• A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer

  2023cites this paper
• BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity

  2023cites this paper
• Genetically engineered mouse models for hereditary cancer syndromes

  2023cites this paper
• Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients

  2023cites this paper
• Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

  2022cites this paper
• Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers

  2022cites this paper
• Oral Contraceptives and BRCA Cancer: A Balancing Act.

  2022cites this paper
• Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

  2022cites this paper
• The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

  2022cites this paper
• RANKL and RANK in Cancer Therapy.

  2022cites this paper
• Update Mammakarzinom 2022 Teil 3 – Brustkrebs in frühen Krankheitsstadien

  2022cites this paper
• Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

  2022cites this paper
• Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature

  2022cites this paper
• Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression

  2022cites this paper
• Beyond the pill: contraception and the prevention of hereditary ovarian cancer

  2022cites this paper
• Associations of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BRCA1/2 Mutation Carriers

  2022cites this paper
• Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation

  2022influential citation
• RANKL blockade for cancer cachexia; a new therapeutic opportunity?

  2022cites this paper
• G-Quadruplex Matters in Tissue-Specific Tumorigenesis by BRCA1 Deficiency

  2022cites this paper
• RANKL biology.

  2022cites this paper
• Promising agents on the horizon

  2021cites this paper
• RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

  2021cites this paper
• SOX factors as cell-state regulators in the mammary gland and breast cancer.

  2021cites this paper
• Role of RANKL in cancer development and metastasis

  2021cites this paper
• Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1

  2021cites this paper
• The Roadmap of RANKL/RANK Pathway in Cancer

  2021cites this paper
• The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.

  2021cites this paper
• Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.

  2021cites this paper
• Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development

  2021cites this paper
• Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development

  2021cites this paper
• Stem Cell Determinant SOX9 Promotes Lineage Plasticity and Progression in Basal-like Breast Cancer

  2020cites this paper
• Progesterone and breast cancer.

  2020cites this paper
• Stem Cells and the Differentiation Hierarchy in Mammary Gland Development.

  2020cites this paper
• BRCA1/P53: Two strengths in cancer chemoprevention.

  2020cites this paper
• Peripheral Blood-Based Biopsy for Breast Cancer Risk Prediction and Early Detection

  2020cites this paper
• RANKL biology: bone metabolism, the immune system, and beyond

  2020cites this paper
• Young Age and Breast Cancer Biology

  2020cites this paper
• NF-κB in the New Era of Cancer Therapy.

  2020cites this paper
• Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer

  2020cites this paper
• Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers

  2020cites this paper
• Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective

  2020cites this paper
• Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

  2020cites this paper
• Pathogenesis of ovarian cancer

  2020cites this paper
• Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes

  2020cites this paper
• The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL

  2020cites this paper
• Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?

  2020cites this paper
• BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.

  2020cites this paper
• Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

  2020cites this paper
• Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey

  2020influential citation
• ERR α promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors

  2020cites this paper
• Osteoclast Signal Transduction Pathways: The RANKL/RANK System

  2019cites this paper
• p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling

  2019cites this paper
• Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.

  2019cites this paper
• RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

  2019cites this paper
• Clinical Impact of RANK Signalling in Ovarian Cancer

  2019cites this paper
• Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis

  2019cites this paper
• Translational highlights in breast cancer research and treatment: recent developments with clinical impact

  2019cites this paper
• Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm

  2019cites this paper
• Osteoimmunology: evolving concepts in bone–immune interactions in health and disease

  2019cites this paper
• Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

  2019cites this paper
• From latency to overt bone metastasis in breast cancer: potential for treatment and prevention

  2019cites this paper